Undertreatment of hypercholesterolaemia: a population‐based study
Open Access
- 8 April 2003
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 55 (4) , 389-397
Abstract
Aims To assess the level of undertreatment of hypercholesterolaemia in the general population, taking intra‐person variability in serum cholesterol concentrations into account, and to identify determinants of undertreatment of hypercholesterolaemia.Methods In this cross‐sectional study, data from two population‐based surveys on cardiovascular disease risk factors conducted between 1987 and 1997 in the Netherlands were used. For all 64 757 respondents aged 20–59 years, treatment eligibility for lipid‐lowering drug use was established according to the Dutch Cholesterol Consensus. Multivariate logistic models were used to identify determinants of undertreatment.Results During the study period, 56.8% of the study population had undesirable cholesterol concentrations (serum total cholesterol> 5 mmol l−1) and 5.5% of those were eligible for pharmacological treatment based on their absolute risk of coronary heart disease. Of those eligible for pharmacological treatment, 16.3% were treated, and 19.6% of those treated had their serum total cholesterol concentration controlled. Only 3.2% of those eligible for pharmacological treatment were both treated and controlled. We identified several determinants for undertreatment, e.g. male gender and younger age for primary prevention and female gender and older age for secondary prevention. Treatment has improved slightly in more recent years.Conclusions Over 95% of the population eligible for the pharmacological treatment of hypercholesterolaemia was either untreated or was uncontrolled. To decrease undertreatment, identification of high‐risk patients should be increased. Those who are treated with lipid‐lowering medication could further benefit from more aggressive treatment, especially with statins.Keywords
This publication has 49 references indexed in Scilit:
- Effect of coronary angiography on use of lipid-lowering agents in women: a report from the women’s ischemia syndrome evaluation (WISE) studyThe American Journal of Cardiology, 2000
- Are Patients With Hyperlipidemia Being Treated?Southern Medical Journal, 2000
- Cardiovascular diseases and risk factors in a population-based study in The Netherlands: agreement between questionnaire information and medical recordsThe Netherlands Journal of Medicine, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Inadequate management of hyperlipidaemia after coronary bypass surgery shown by medical audit.Heart, 1994
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)The Lancet, 1994
- Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel1993
- Cardiovascular disease risk profilesAmerican Heart Journal, 1991